The characterization of acute myeloid leukemia and endometrial cancer are the latest results of The Cancer Genome Atlas Research Network’s efforts to sequence the genomes of 20 major cancers. The photo above shows technicians from The Genome Institute at Washington University in St. Louis.
More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population. Depicted are members of NCI’s Pediatric Oncology Branch. From left: Drs. Crystal Mackall, Daniel Lee, and Alan Wayne
A year ago, Colleen Williams was into the natural look. She seldom bothered to put on makeup and she let her long, wavy, brown hair flow free. Cancer treatment changed that. These days, when she feels well enough to go to work, Williams wears her “cute hat” to cover her newly-balding head and takes a little extra time in the morning to pencil in her thinning brows and apply concealer to make her skin look a little less gray.
The Living Lab is an innovative partnership between NIH institutes and private industry, to use cutting-edge electron microscopy to navigate into cells and viruses. Sriram Subramaniam, Ph. D., director of the NIH component of the Living Lab, is pictured holding a model of the three-dimensional structure of a portion of a protein complex from the surface of HIV.
Sometimes rising or falling trends in cancer rates can mask more complicated scientific aspects of the disease. Consider a relatively rare form of leukemia known as AML that predominantly affects middle-age and elderly adults. Based on data from NCI and others recently released in the Annual Report to the Nation, an estimated 14,000 people will develop AML in the United States in 2013, and an estimated 10,000 people will die from it.
The Annual Report to the Nation on the Status of Cancer, 1975–2009, shows that overall cancer death rates continued to decline in the U.S. among both men and women, among all major racial and ethnic groups, and for all of the most common cancer sites.
- Experimental drug beneficial in NIH trial to treat a rare sarcomaMay 2, 2013
- TCGA researchers identify potential drug targets, markers for leukemia riskMay 1, 2013
- Study establishes basis for genomic classification of endometrial cancersMay 1, 2013
- A drug target that stimulates development of healthy stem cellsApril 17, 2013
Obtaining an NCI designation for a cancer center is usually a years-long process of building — facilities, faculty, and most importantly, a research portfolio — culminated by a rigorous review process. Selection provides recognition of research excellence